Supplementary Material for: Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies

Carla Nester (Contributor)
Gerald Appel (Contributor)
Andrew S. Bomback (Contributor)
K. Bouman (Contributor)
H. T. Cook (Contributor)
Erica Daina (Contributor)
Bradley P. Dixon (Contributor)
Kara Rice (Contributor)
Nader Najafian (Contributor)
James Hui (Contributor)
Craig Langman (Contributor)
Liz Lightstone (Contributor)
Samir V. Parikh (Contributor)
Matthew C. Pickering (Contributor)
C. John Sperati (Contributor)
Howard Trachtman (Contributor)
James Tumlin (Contributor)
Jack Wetzels (Contributor)
Giuseppe Remuzzi (Contributor)

Dataset

1 Article

1 results

2023
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies
Nester, C., Appel, G. B., Bomback, A. S., Bouman, K. P., Cook, H. T., Daina, E., Dixon, B. P., Rice, K., Najafian, N., Hui, J., Podos, S. D., Langman, C. B., Lightstone, L., Parikh, S. V., Pickering, M. C., Sperati, C. J., Trachtman, H., Tumlin, J., De Vries, A. P. J., Wetzels, J. F. M., & 1 othersRemuzzi, G., Jan 1 2023, In: American Journal of Nephrology. 53, 10, p. 687-700 14 p.
Research output: Contribution to journal › Article › peer-review

Open Access
2 Scopus citations